A landmark medical advance in May 2025 saw the FDA approve and doctors deliver a customized CRISPR treatment directly to a patient—an infant with CPS1 deficiency. This bespoke gene-editing approach was made and given within six months, providing a proof-of-concept for rapid, individually tailored cures for rare diseases. As gene editing platforms develop, this breakthrough demonstrates a future where genetically targeted therapies become routine, potentially curing conditions once thought untreatable at the source.
Source: Innovative Genomics Institute
Link: https://innovativegenomics.org/news/crispr-clinical-trials-2025/






Leave a Reply